SOPHiA GENETICS (NASDAQ:SOPH) Reaches New 52-Week High - Time to Buy?

Key Points

• SOPHiA GENETICS reached a new 52-week high of $7.88, with shares recently trading near $7.67 and above their 50-day and 200-day moving averages.
• Analyst sentiment is mixed: three analysts rate the stock Buy, one Hold and one Sell. The average rating is Hold, with an average price target of $10, while HC Wainwright raised its target to $14 and BTIG to $9.
• The company exceeded revenue expectations but missed quarterly EPS estimates, reporting a $0.26 loss per share versus a projected $0.21 loss. SOPHiA GENETICS remains unprofitable, with a negative net margin of 93.86%, while insiders have sold more than 309,000 shares over the past 90 days.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) hit a new 52-week high on Tuesday . The stock traded as high as $7.88 and last traded at $7.67, with a volume of 408022 shares. The stock had previously closed at $7.71.

Wall Street Analyst Weigh In

SOPH has been the topic of several recent analyst reports. HC Wainwright upped their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Zacks Research upgraded shares of SOPHiA GENETICS to a "hold" rating in a research note on Tuesday, July 21st. BTIG Research boosted their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $10.00.

SOPHiA GENETICS Trading Down 0.5%

The stock has a 50-day simple moving average of $5.68 and a 200 day simple moving average of $5.16. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The company has a market cap of $643.44 million, a price-to-earnings ratio of -6.67 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. As a group, equities research analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Insider Transactions at SOPHiA GENETICS

In other SOPHiA GENETICS news, insider Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $5.66, for a total transaction of $28,300.00. Following the completion of the sale, the insider directly owned 223,387 shares in the company, valued at approximately $1,264,370.42. The trade was a 2.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CTO Abhimanyu Verma sold 5,000 shares of the company's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $7.60, for a total transaction of $38,000.00. Following the completion of the sale, the chief technology officer directly owned 182,171 shares in the company, valued at $1,384,499.60. This trade represents a 2.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 309,592 shares of company stock worth $1,884,635 in the last ninety days. Corporate insiders own 4.88% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. First Dallas Securities Inc. purchased a new stake in SOPHiA GENETICS in the first quarter valued at $50,000. Squarepoint Ops LLC acquired a new stake in SOPHiA GENETICS during the 3rd quarter worth about $49,000. Perkins Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS during the 4th quarter valued at about $49,000. Quadrature Capital Ltd purchased a new position in shares of SOPHiA GENETICS during the 4th quarter valued at about $54,000. Finally, XTX Topco Ltd acquired a new position in shares of SOPHiA GENETICS in the 4th quarter valued at about $55,000. Hedge funds and other institutional investors own 31.59% of the company's stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source